Ascorbic Acid-PEI Carbon Dots with Osteogenic Effects as miR-2861 Carriers to Effectively Enhance Bone Regeneration
Wenhuan Bu,Xiaowei Xu,Zilin Wang,Nianqiang Jin,Lili Liu,Jie Liu,Shoujun Zhu,Kai Zhang,Raz Jelinek,Ding Zhou,Hongchen Sun,Bai Yang
DOI: https://doi.org/10.1021/acsami.0c15425
2020-10-29
Abstract:Nucleic acid transfer has shown significant potential in the treatment of bone damage because of its long lasting local effect and lower cost. Nonviral vectors, such as nanomaterials, with higher biocompatibility are increasedly applied in the study of bone defect repair. Carbon dots with various reactive groups on the surface not only provide a unique surface to carry therapeutic genes, but also some carbon dots have been reported to promote osteogenic differentiation. The bone regeneration effect of carbon dots <i>in vivo</i>, however, is rarely investigated. MiR-2861 has revealed osteogenic differentiation effects. In the current study, we created ascorbic acid-PEI carbon dots (CD), which were able to carry miR-2861, by the microwave-assisted pyrolysis method. Results demonstrated that CD had excellent fluorescence stability leading to good fluorescence imaging <i>in vitro</i> and <i>in vivo</i>. CD was efficiently internalized into bone marrow stromal cells (BMSCs) through the clathrin-mediated endocytosis pathway and distributed in the mitochondria, endoplasmic reticulum, lysosome, and nucleus. Results from alkaline phosphatase staining, alizarin red staining, and reverse transcription real-time PCR (RT-QPCR) showed that our CD indeed had osteogenic effects <i>in vitro</i>. Flow cytometry data indicated that CD could efficiently deliver miR-2861 into BMSCs <i>in vitro</i>, and CD carrying miR-2861 () had the strongest osteogenic effects. Analyses of hematology, serum biochemistry, and histology showed that CD and did not have cytotoxicity and had higher biocompatibility <i>in vivo</i>. Most interestingly, CD and miR-2861 in the could act synergistically to promote osteogenic differentiation <i>in vitro</i> and new bone regeneration <i>in vivo</i> remarkably. Our results clearly indicate that the osteogenic CD delivering osteogenic therapeutic gene, miR-2861, can obtain much stronger bone regeneration ability, suggesting that our CD has great potential in future clinical application.This article has not yet been cited by other publications.
materials science, multidisciplinary,nanoscience & nanotechnology